[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100311460":3},{"organization":4,"armGroups":7,"interventions":38,"overallOfficials":10,"centralContacts":52,"locations":61,"responsibleParty":213,"collaborators":215,"id":221,"slug":222,"hasResults":223,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":10,"eligibilityCriteria":227,"healthyVolunteers":228,"sex":229,"minAge":230,"maxAge":10,"enrollmentInfo":231,"targetDuration":10,"studyType":234,"phases":10,"briefSummary":235,"conditions":236,"keywords":241,"overallStatus":64,"whyStopped":10,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":252},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8,15,19,23,28,31,34],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1: Advanced PDAC cohort",null,"Blood and sweat samples will be drawn from patients prior to starting treatment. A research biopsy may be performed for tissue analysis (ATAC-Array) (optional). This cohort is actively accruing.",[13,14],"Diagnostic Test: Blood Draw","Diagnostic Test: Tumor Tissue Collection",{"label":16,"type":10,"description":17,"interventionNames":18},"Cohort 2: Operable PDAC cohort","Blood samples will be drawn from patients prior to operation. Tissue from surgical sample may be analyzed (ATAC-Array) (optional). This cohort is actively accruing.",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Cohort 3: Acute Benign Pancreatic Pathology Cohort","Blood samples will be drawn during acute episode of disease and every 6 to 12 months thereafter, per institutional guidelines. This cohort is closed to accrual.",[13],{"label":24,"type":10,"description":25,"interventionNames":26},"Cohort 4: Chronic Benign Pancreatic Pathology, IPMN and Pancreatic Cyst Cohorts","Blood samples will be drawn at study enrollment and every 6 to 12 months thereafter, per institutional guidelines. This cohort is closed to accrual.",[13,27],"Diagnostic Test: Cyst Fluid",{"label":29,"type":10,"description":25,"interventionNames":30},"Cohort 5: Chronic Benign Pancreatic Pathology, IPMN and Pancreatic Cyst Cohorts",[13,27],{"label":32,"type":10,"description":25,"interventionNames":33},"Cohort 6: Chronic Benign Pancreatic Pathology, IPMN and Pancreatic Cyst Cohorts",[13,27],{"label":35,"type":10,"description":36,"interventionNames":37},"Cohort 7: Healthy Controls","Blood samples will be collected at study enrollment only. This cohort is closed to accrual.",[13],[39,44,48],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":10},"DIAGNOSTIC_TEST","Blood Draw","If clinically safe, up to approximately 50ml of blood will be drawn, not to exceed the following criteria:\n\nPatients and controls weighing 50kg or more\n\n* For draw amounts up to 50mL, there is no required hemoglobin threshold.\n* For amounts exceeding 50mL, patients who meet standard blood banking criteria (e.g., hemoglobin values within normal limits and minimum weight of 50kg) may give as much as a full unit of blood (500mL) at one time or in divided fractions over a 56 day\u002Feight week period.\n\nPatients and controls weighing \\\u003C 50kg\n\n* For patients whose hemoglobin is below normal limits but at least 7.0 gm\u002FdL, no more than a total of 50 ml of blood or 5 ml\u002Fkg, whichever is less, may be collected per 56 day\u002Feight week period, but no more than approximately 2 ml\u002Fkg of blood at any one time.",[9,16,20,24,29,32,35],{"type":40,"name":45,"description":46,"armGroupLabels":47,"otherNames":10},"Tumor Tissue Collection","Tumor tissue will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere",[9,16],{"type":40,"name":49,"description":50,"armGroupLabels":51,"otherNames":10},"Cyst Fluid","Cyst fluid will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere",[24,29,32],[53,58],{"name":54,"role":55,"phone":56,"phoneExt":10,"email":57},"Kenneth Yu, MD","CONTACT","646-888-4188","yuk1@mskcc.org",{"name":59,"role":55,"phone":60,"phoneExt":10,"email":10},"David Kelson, MD","646-888-4179",[62,79,90,105,116,127,136,144,154,163,174,189,201],{"facility":63,"status":64,"city":65,"state":66,"zip":67,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":76},"Memorial Sloan Kettering Monmouth (All protocol activities)","RECRUITING","Middletown","New Jersey","07748","United States","US",{"type":71,"coordinates":72},"Point",[73,74],-74.11709,40.39428,{"lat":74,"lon":73},[77],{"name":78,"role":55,"phone":56,"phoneExt":10,"email":10},"Kenneth Yu, MD, M.Sc.",{"facility":80,"status":64,"city":81,"state":66,"zip":82,"country":68,"countryCode":69,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Memorial Sloan Kettering Bergen (All protocol activities)","Montvale","07645",{"type":71,"coordinates":84},[85,86],-74.02292,41.04676,{"lat":86,"lon":85},[89],{"name":78,"role":55,"phone":56,"phoneExt":10,"email":10},{"facility":91,"status":92,"city":93,"state":94,"zip":95,"country":68,"countryCode":69,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"Cold Springs Harbor Laboratory (Specimen Analysis)","NOT_YET_RECRUITING","Cold Spring Harbor","New York","11724",{"type":71,"coordinates":97},[98,99],-73.45679,40.87149,{"lat":99,"lon":98},[102],{"name":103,"role":55,"phone":104,"phoneExt":10,"email":10},"David Tuveson, MD, PhD","516-367-5246",{"facility":106,"status":64,"city":107,"state":94,"zip":108,"country":68,"countryCode":69,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"Memorial Sloan Kettering Cancer Center @ Commack (All Protocol Activities)","Commack","11725",{"type":71,"coordinates":110},[111,112],-73.29289,40.84288,{"lat":112,"lon":111},[115],{"name":78,"role":55,"phone":56,"phoneExt":10,"email":10},{"facility":117,"status":64,"city":118,"state":94,"zip":119,"country":68,"countryCode":69,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Memorial Sloan Kettering Westchester (All protocol activities)","Harrison","10604",{"type":71,"coordinates":121},[122,123],-73.71263,40.96899,{"lat":123,"lon":122},[126],{"name":78,"role":55,"phone":56,"phoneExt":10,"email":10},{"facility":128,"status":129,"city":94,"state":94,"zip":130,"country":68,"countryCode":69,"cosmosGeoPoint":131,"geoPoint":135,"contacts":10},"New York University","ACTIVE_NOT_RECRUITING","10010",{"type":71,"coordinates":132},[133,134],-74.00597,40.71427,{"lat":134,"lon":133},{"facility":137,"status":64,"city":94,"state":94,"zip":138,"country":68,"countryCode":69,"cosmosGeoPoint":139,"geoPoint":141,"contacts":142},"Memorial Sloan - Kettering Cancer Center","10021",{"type":71,"coordinates":140},[133,134],{"lat":134,"lon":133},[143],{"name":54,"role":55,"phone":56,"phoneExt":10,"email":10},{"facility":145,"status":64,"city":94,"state":94,"zip":146,"country":68,"countryCode":69,"cosmosGeoPoint":147,"geoPoint":149,"contacts":150},"Memorial Sloan Kettering Basking Ridge (All protocol activities)","10065",{"type":71,"coordinates":148},[133,134],{"lat":134,"lon":133},[151,152],{"name":78,"role":55,"phone":56,"phoneExt":10,"email":10},{"name":153,"role":55,"phone":10,"phoneExt":10,"email":10},"S",{"facility":155,"status":92,"city":94,"state":94,"zip":146,"country":68,"countryCode":69,"cosmosGeoPoint":156,"geoPoint":158,"contacts":159},"Weill Cornell Medical Center",{"type":71,"coordinates":157},[133,134],{"lat":134,"lon":133},[160],{"name":161,"role":55,"phone":162,"phoneExt":10,"email":10},"David Lyden, MD","212-746-6565",{"facility":164,"status":64,"city":165,"state":94,"zip":166,"country":68,"countryCode":69,"cosmosGeoPoint":167,"geoPoint":171,"contacts":172},"Memorial Sloan Kettering Nassau (All protocol activities)","Rockville Centre","11553",{"type":71,"coordinates":168},[169,170],-73.64124,40.65871,{"lat":170,"lon":169},[173],{"name":78,"role":55,"phone":56,"phoneExt":10,"email":10},{"facility":175,"status":92,"city":176,"state":10,"zip":177,"country":178,"countryCode":179,"cosmosGeoPoint":180,"geoPoint":184,"contacts":185},"Sha'are Zedek Medical Center","Jerusalem","91031","Israel","IL",{"type":71,"coordinates":181},[182,183],35.21633,31.76904,{"lat":183,"lon":182},[186],{"name":187,"role":55,"phone":188,"phoneExt":10,"email":10},"Ephrat Levy-Lahad, PhD","646-497-2600",{"facility":190,"status":92,"city":191,"state":10,"zip":10,"country":178,"countryCode":179,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"Weizmann Institute of Science","Rehovot",{"type":71,"coordinates":193},[194,195],34.81199,31.89421,{"lat":195,"lon":194},[198],{"name":199,"role":55,"phone":200,"phoneExt":10,"email":10},"Avigdor Scherz, PhD","972 8-934-2111",{"facility":202,"status":64,"city":203,"state":10,"zip":10,"country":178,"countryCode":179,"cosmosGeoPoint":204,"geoPoint":208,"contacts":209},"Sheba Medical Center","Tel Litwinsky",{"type":71,"coordinates":205},[206,207],34.84588,32.05096,{"lat":207,"lon":206},[210],{"name":211,"role":55,"phone":212,"phoneExt":10,"email":10},"Talia Golan, MD","03-5303295",{"type":214,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[216,218,220],{"name":202,"class":217},"OTHER_GOV",{"name":219,"class":6},"Weill Medical College of Cornell University",{"name":190,"class":6},"100311460","a-study-of-blood-based-biomarkers-for-pancreas-adenocarcinoma-100311460",false,"NCT03334708","A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma","Development of Biomarkers for the Early Detection, Surveillance and Monitoring of Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\nCohort 1: Advanced Pancreatic Cancer Cohort Inclusion Criteria\n\n* Radiological, histological or cytological confirmed diagnosis of locally advanced or metastatic pancreatic adenocarcinoma by the enrolling institution\n* Patient planning to receive systemic treatment\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n* Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).\n\nCohort 2: Operable Pancreatic Cancer Cohort Inclusion Criteria\n\n* Radiological, histological or cytological confirmed diagnosis of pancreatic adenocarcinoma by the enrolling institution\n* Patient planned to undergo upfront resection\n* No pre-operative systemic therapy nor chemoradiation therapy planned\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n* Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).\n\nCohort 3: Acute Benign Pancreatic Pathology Control Inclusion Criteria\n\n* Confirmed diagnosis of acute pancreatitis or other acute pancreatic pathology by the enrolling institution\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n\nCohort 4: Chronic Benign Pancreatic Pathology Control Inclusion Criteria\n\n* Confirmed diagnosis of chronic pancreatitis or other non-cystic chronic pancreatic pathology by the enrolling institution\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n\nCohort 5: IPMN Control Inclusion Criteria\n\n* Confirmed diagnosis of IPMN without high risk features by the enrolling institution\n* A minimum age of 18 years old\n\nCohort 6: Pancreatic Cyst Control Inclusion Criteria\n\n* Confirmed diagnosis of benign pancreatic cyst by the enrolling institution\n* A minimum age of 18 years old\n\nCohort 7: Healthy Control Inclusion Criteria\n\n* A minimum age of 18 years old\n\nExclusion Criteria:\n\nCohort 1: Advanced Pancreatic Cancer Cohort Exclusion Criteria\n\n* Prior chemotherapy or radiation therapy for pancreatic cancer within the last 3 months in the localized setting\n* Active second malignancy, unless low grade malignancy\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 2: Operable Pancreatic Cancer Cohort Exclusion Criteria\n\n* Neoadjuvant chemotherapy or radiation therapy is planned\n* Active second malignancy, unless low grade malignancy\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 3: Acute Benign Pancreatic Pathology Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 4: Chronic Benign Pancreatic Pathology Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 5: IPMN Control Exclusion Criteria\n\n* IPMN with high risk features or planned resection\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 6: Pancreatic Cyst Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 7: Healthy Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures",true,"ALL","18 Years",{"count":232,"type":233},120,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.",[237,238,239,240],"Pancreatic Cancer","Pancreatic Diseases","Pancreatitis","Pancreatic Cyst",[242],"17-257","2026-08-12",{"date":245,"type":246},"2026-08-14","ACTUAL",{"date":248,"type":246},"2017-10-30",{"date":250,"type":233},"2026-10-30",{"name":5,"class":6},13]